Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 415 clinical trials
Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis (BosuPeg)

myeloid leukemia patients, and to estimate efficacy of the addition of RoPegIFN to BOS in terms of deep molecular response with the aim of increasing the proportion of patients who may achieve treatment

anagrelide
remission
leukemia
interferon
hydroxyurea
  • 1 views
  • 27 Apr, 2022
  • 5 locations
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib (DANTE)

Leukemia - Chronic Phase (CML-CP) treated with first-line nilotinib who reached a sustained deep molecular response before entering the study.

leukemia
chronic phase chronic myeloid leukemia
nilotinib
lipase
remission
  • 3 views
  • 27 Apr, 2022
  • 5 locations
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors to support related indication registration in China. The primary objective of the study is to

basophils
tyrosine
leukemia
asciminib
  • 0 views
  • 06 May, 2022
  • 9 locations
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. …

stem cell transplantation
leukemia
hematologic malignancy
myeloid leukemia
minimal residual disease
  • 0 views
  • 10 Apr, 2022
  • 1 location
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK

lymphoid leukemia
g-csf
neutrophil count
monoclonal protein
platelet count
  • 0 views
  • 26 Apr, 2022
  • 1 location
Study to Evaluate the Safety and Tolerability of EP0042

, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

azacitidine
cancer
mylotarg
cytarabine
midostaurin
  • 1 views
  • 15 May, 2022
  • 3 locations
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

This research study is studying cytokine induced memory-like natural killer (CIML NK) cells plus IL-2 in adult patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and

leukemia
fludarabine
hemolysis
flow cytometry
tacrolimus
  • 4 views
  • 10 May, 2022
  • 1 location
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

This phase II trial studies how well azacitidine and venetoclax with or without pembrolizumab work in treating older patients with newly diagnosed acute myeloid leukemia. Chemotherapy drugs

azacitidine
lymphoma
tretinoin
cancer
hematologic disorder
  • 0 views
  • 27 Apr, 2022
  • 24 locations
Safety and Efficacy Evaluation of CD19-UCART

The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.

fludarabine
cyclophosphamide
  • 29 views
  • 27 Apr, 2022
  • 2 locations
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

leukemia. Navtemadlin may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Chemotherapy drugs, such as cytarabine and idarubicin, work in different ways to

ejection fraction
idarubicin
enasidenib
hemolysis
cancer
  • 0 views
  • 30 Apr, 2022
  • 2 locations